Denali Therapeutics Inc (DNLI)

NASD · Healthcare · Biotechnology · USA

Denali Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Denali Therapeutics is a biopharmaceutical company discovering and developing medicines for serious diseases by using its proprietary TransportVehicle technology to deliver large molecule therapeutics across the blood-brain barrier. The company has programs in rare lysosomal storage disorders and common neurodegenerative diseases including Alzheimer's and Parkinson's disease, with a clinical-stage portfolio spanning enzyme, oligonucleotide, and antibody therapeutics.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Denali Therapeutics Inc stock.

Our verdict on DNLI

Overvalued: intrinsic value $3.32 per share, market price $18.00, margin of safety -442.6% (as of 2026-11-17).

A 2.4x revenue multiple, discounted for its losses, values the shares at $3.32; the price of $18.00 is 443% above that value.

ETFs with the most weight in DNLI

17 more funds hold it; the full list is part of the paid plan.

More on DNLI

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than DNLI in Biotechnology

89 more in this industry show a wider margin of safety.

Is DNLI undervalued or overvalued?

DNLI is overvalued (as of the 2026-11-17 close). A 2.4x revenue multiple, discounted for its losses, values the shares at $3.32; the price of $18.00 is 443% above that value.

What is the intrinsic value of DNLI?

$3.32 per share (as of the 2026-11-17 close), against a market price of $18.00. That is a margin of safety of -442.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.